Muhammad Naeem

Muhammad Naeem is a Postdoctoral Researcher at the Institute of Community Medicine, University Medicine Greifswald, specializing in epidemiological investigations of metabolic diseases. His primary affiliation is with Till Itterman's Lab within the Study of Health in Pomerania (SHIP) consortium, with additional affiliations at the Max Planck Institute for Demographic Research and DGepi (German Society for Epidemiology). Previously associated with the Department of Zoology at University of Malakand, Pakistan, his research bridges population health and clinical medicine.

Dr. Naeem's research focuses on the epidemiology of metabolic disorders, with particular emphasis on body composition analysis, hepatic/splenic volume assessment, and their relationships with diabetes, cardiovascular risks, and mortality. His work uniquely compares measurement modalities (anthropometry, bioelectrical impedance, MRI) to determine optimal biomarkers for disease prediction. Current investigations examine sex-specific lipid mediator effects, organ volume-fitness relationships, and longitudinal inflammatory dynamics.

His publication record shows significant productivity with 12 peer-reviewed articles (2016-2025), including 8 in the last three years. Analysis of his recent work reveals a strong trend toward multimodal assessment of body composition and organ volumes as predictors of metabolic disease, with increasing methodological sophistication in longitudinal and sex-stratified analyses. Research consistently leverages the SHIP cohort's rich dataset combining clinical, imaging, and biochemical parameters.

• Member of DGepi (German Society for Epidemiology)
• Affiliated with Max Planck Institute for Demographic Research
• Active contributor to SHIP study consortium

Dr. Naeem's research program demonstrates robust institutional support through access to the SHIP cohort infrastructure, including advanced imaging facilities and population databases. His collaborative network spans multiple German research institutions and international partners, facilitating comprehensive investigations into metabolic disease pathways. The lab environment emphasizes rigorous epidemiological methods and translational applications of population findings to clinical practice.